Stable plinabulin formulations and methods of making and using same
By using propylene glycol and polyethylene glycol 15 hydroxystearate in the punabrin preparation, combined with light-proof packaging of amber glass container and a light-shielding sleeve, the stability problems caused by the agent to light sensitivity are solved. Long-term stability and efficient administration of the formulation are achieved.
Patent Information
- Application Number
- CN202380029269.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-02
- Filing Date
- 2023-02-08
- Publication Date
- 2024-12-06
AI Technical Summary
Existing agents are sensitive to light or air, resulting in stability problems and it is difficult to maintain the effectiveness of the therapeutic agent during storage or use.
Liquid preparations containing punabrin, propylene glycol and polyethylene glycol 15 hydroxystearate are used, and UV light is blocked through measures such as amber glass container and a light shielding sleeve, providing light-proof packaging to protect the agent.
The stability of the pronabrin preparation is significantly improved, ensuring high concentrations and low impurity content for a longer period of time, prolonging shelf life and protecting the drug during administration.
Smart Images

Figure CN119095568A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This patent application claims priority to U.S. Provisional Application No. 63 / 308,723, filed on February 10, 2022, and U.S. Provisional Application No. 63 / 337,256, filed on May 2, 2022. The entire contents of all of the above applications are incorporated herein by reference in their entirety for all purposes. Field of the Invention
[0003] The present invention relates to the fields of chemistry and medicine. More specifically, the present invention relates to a stable Plinabulin formulation and a method for preparing and using the same.
[0004] background
[0005] Many preparations that comprise therapeutic agents are sensitive to one or more elements or conditions, which makes them unstable after a period of time. One such element or condition is the sensitivity to one or more elements of air or light. Another such element or condition is to have gas or dissolved gas in the preparation, or to expose one or more elements of the preparation to light, pollutants or organisms such as bacteria. Another such condition or element is the relative amount of a specific molecule and one or more components in the preparation, including but not limited to the activating agent of the preparation. Therefore, a kind of preparation is needed, which comprises a pharmaceutical preparation, which can keep the stability of one or more therapeutic agents or other elements in the preparation comprising the therapeutic agent when storing for a period of time or during the therapeutic agent application. SUMMARY OF THE INVENTION
[0007] The present invention provides stable Plinabulin formulations and methods for preparing and using the same. In certain aspects, the present invention describes a container. In some embodiments, the container comprises a liquid formulation comprising Plinabulin, propylene glycol, and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate), wherein the container is configured to block at least 85% of ultraviolet / visible light between 290nm and 450nm. In some embodiments, the container is a disposable amber glass vial. In some embodiments, the amber glass vial further comprises a rubber stopper and a flip cap. In some embodiments, the rubber stopper is a chlorobutyl rubber stopper with a B2-40 coating. In some embodiments, the rubber stopper further comprises a plug portion, wherein the plug portion comprises a Flurotec coating. In some embodiments, the container is an intravenous (IV) bag. In some embodiments, the container is an IV bag covered by a light-shielding sleeve. In some embodiments, the container is an IV tube located within a light-shielding sleeve. In some embodiments, the concentration of Plinabulin in the liquid formulation is about 40mg / 10ml. In some embodiments, the liquid formulation comprises propylene glycol and polyethylene glycol 15 hydroxystearate (PEG1 5-hydroxystearate) in a ratio of 60:40 (by weight). In some embodiments, the liquid formulation comprises less than 0.5% of ether impurities. In some embodiments, the liquid formulation comprises less than 0.5% of alcohol impurities. In some embodiments, the liquid formulation comprises less than 0.5% of water. In some embodiments, the liquid formulation comprises less than 2.0% of total impurities.
[0008] In certain aspects, the present invention describes a kit. In some embodiments, the kit includes Plinabulin and light-proof packaging placed in a light-proof container, wherein the light-proof container blocks at least 85% of ultraviolet / visible light between 290nm and 450nm. In some embodiments, the concentration of Plinabulin in the liquid formulation is about 40mg / 10ml. In some embodiments, the Plinabulin is in a liquid formulation containing propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In some embodiments, the liquid formulation contains 60:40 (weight percent) of propylene glycol and polyethylene glycol 15 hydroxystearate (PEG1 5-hydroxystearate). In some embodiments, the light-proof container is an amber vial. In some embodiments, the light-proof container further includes a rubber stopper and a flip cap. In some embodiments, the rubber stopper is a chlorobutyl rubber stopper with a B2-40 coating. In some embodiments, the rubber stopper further includes a plug head portion, wherein the plug head portion includes a Flurotec coating. In some embodiments, the light-proof packaging includes solid black printing on its interior. In some embodiments, the kit further comprises an IV bag. In some embodiments, the IV bag is configured to block at least 85% of UV / visible light between 290nm and 450nm. In some embodiments, the IV bag comprises a light shielding sleeve. In some embodiments, the kit further comprises an IV tube. In some embodiments, the IV tube is configured to block at least 85% of UV / visible light between 290nm and 450nm. In some embodiments, the IV tube comprises a light shielding sleeve.
[0009] In certain aspects, the present invention describes a method of administering Plinabulin to a subject. In some embodiments, the method of administering Plinabulin to a subject in need thereof comprises providing Plinabulin in a light-proof IV bag and administering Plinabulin to the subject in need thereof through a light-proof IV tube. In some embodiments, the light-proof IV bag blocks at least 85% of UV / visible light between 290nm and 450nm. In some embodiments, the light-proof IV tube blocks at least 85% of UV / visible light between 290nm and 450nm. In some embodiments, the method comprises providing the Plinabulin, comprising injecting the Plinabulin into a light-proof IV bag. In some embodiments, the method comprises providing the Plinabulin, comprising injecting the Plinabulin into a non-light-proof IV bag and then placing a light-shielding sleeve on the non-light-proof IV bag. In some embodiments, the Plinabulin is injected into D5W as a liquid formulation. In some embodiments, the liquid formulation comprises propylene glycol and polyethylene glycol 15 hydroxystearate (PEG1 5-hydroxystearate). In some embodiments, the liquid formulation comprises propylene glycol and polyethylene glycol 15 hydroxystearate (PEG 15-hydroxystearate) in a ratio of 60:40 (by weight). In some embodiments, the liquid formulation comprises Plinabulin at a concentration of about 40 mg / 10 ml. In some embodiments, the method comprises placing a non-light-shielding IV tube in a light-shielding sleeve to form a light-shielding IV tube.
[0010] BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 is a schematic diagram of a box in one embodiment of the present invention.
[0012] Figure 2 is a picture of an amber IV bag cover in one embodiment of the present invention.
[0013] Figure 3 is a picture of an amber IV tube cover in accordance with one embodiment of the present invention.
[0014] Detailed description
[0015] Described herein are Plinabulin unit dosage forms, kits, and methods of making and using Plinabulin compositions. Plinabulin, (3Z,6Z)-3-Benzylidene-6-{[5-(2-methyl-2-propyl)-1H-imidazol-4-yl]methylene}-2,5-piperazinedione, is a synthetic analog of the natural compound phenylahistin. Plinabulin can be readily prepared according to the methods and procedures described in detail in U.S. Patent Nos. 7,064,201 and 7,919,497, the entire contents of which are incorporated herein by reference.
[0016] Before further describing the present invention, it should be understood that the present invention is not limited to the specific embodiments described, as these embodiments may of course vary. It should also be understood that the terminology used in the present invention is only used to describe specific embodiments and is not intended to be limiting, as the scope of the present invention will be limited only by the appended claims.
[0017] When providing a numerical range, it should be understood that, unless the context clearly specifies otherwise, each intermediate value (to one tenth of the unit of the lower limit) between the upper and lower limits of the range, as well as any other described numerical values or intermediate values within the range, are included in the present invention. The upper and lower limits of these smaller ranges can be independently included in the smaller range and are also included in the present invention, subject to any specifically excluded limits in the described range. When the described range includes one or two of the described limits, the scope excluding one or two of these included limits is also included in the present invention.
[0018] The method described in the present invention may be implemented in any order of the events that are logically possible, or may be implemented in the order of events described in the present invention.
[0019] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, preferred methods and materials are now described.
[0020] All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited.
[0021] It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that the claims may be drafted to exclude any optional elements. As such, this statement is intended to serve as a prerequisite basis for use of the terminology "only," "only" and the like when reciting claim elements or using a "negative" limitation.
[0022] The publications discussed herein are provided only for their disclosure prior to the filing date of the present application. Nothing herein should be construed as admitting that the present invention is not entitled to precede such publications based on prior inventions. In addition, the publication dates provided may be different from the actual publication dates and may require separate confirmation.
[0023] definition
[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. The entire contents of all patents, applications, published applications, and other publications are incorporated herein by reference. If there are multiple definitions for a term herein, the definition in this section shall prevail unless otherwise stated.
[0025] The term "agent" is used in the present invention to refer to a compound, a mixture of compounds, a biomacromolecule, or an extract made from biological material.
[0026] The terms "cancer", "tumor" and "cancer" are used interchangeably in the present invention to refer to cells that exhibit relatively autonomous growth, so they exhibit an abnormal growth phenotype characterized by a significant loss of cell proliferation control. In general, cells of interest for detection or treatment in the present application include precancerous (e.g., benign) cells, malignant cells, pre-metastatic cells, metastatic cells, and non-metastatic cells. The detection of cancer cells is particularly interesting.
[0027] As used herein, the term "subject" refers to a human or non-human mammal, such as a dog, cat, mouse, rat, cow, sheep, pig, goat, non-human primate, or bird such as chicken, as well as any other vertebrate or invertebrate.
[0028] The term "mammal" is used in its usual biological sense. Thus, it specifically includes, but is not limited to, primates, including great apes (chimpanzees, apes, monkeys) and humans, cows, horses, sheep, goats, pigs, rabbits, dogs, cats, rodents, rats, mice, guinea pigs, etc.
[0029] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a dose of a therapeutic agent that is effective to alleviate or reduce the likelihood of onset of one or more symptoms of a disease or condition to some extent, and may include curing the disease or condition.
[0030] The term "liquid preparation" used in the present invention refers to a pharmaceutical preparation containing a mixture of an active pharmaceutical ingredient and a non-pharmaceutical ingredient (excipient) dissolved or suspended in a suitable solvent or solvent mixture. The liquid dosage form can be provided as a ready-to-use liquid or a powder for reconstitution. The liquid dosage form can be a single-phase liquid dosage form and a biphasic liquid dosage form.
[0031] It is generally preferred to administer the compounds of the invention in intravenous or subcutaneous unit dosage forms; however, other routes of administration may also be considered. Contemplated routes of administration include, but are not limited to, oral administration, parenteral administration, intravenous administration, and subcutaneous administration. The compounds in preferred embodiments may be formulated into liquid preparations for, for example, oral administration. Suitable dosage forms include suspensions, syrups, elixirs, and the like. Oral liquids are generally non-sterile, while liquids administered by parenteral routes may be sterile and non-sterile preparations.
[0032] The compounds of the present invention can be combined with suitable carriers, diluents or excipients (such as sterile water, physiological saline, glucose, etc.), and according to the route of administration and preparation requirements, they may contain auxiliary substances such as wetting agents or emulsifiers, pH buffers, gelling or thickening additives, preservatives, flavoring agents, coloring agents, etc. See, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 20th Edition (June 1, 2003) and Remington's Pharmaceutical Sciences, Mack Pub. Co; 18th and 19th Editions (December 1985 and June 1990, respectively). Ansel, H. (2010). Pharmaceutical Calculations, (13th Edition). London: Wolters Kluwer Health and Lippincott Williams & Wilkins, Chaudhari, S and Patil, P. (2012). Pharmaceutical Excipients: A review. International Journal of Progress in Pharmacy, Biology and Chemistry, 1(1): 21-34, Denton, P and Rostron, C (2013). Pharmaceutics: The Science of Medicine Design. Oxford University Press, UK, Gautami, J. (2016). Liquid Dosage Forms. Nanoscience and Nanotechnology, 10(3): 1-9.
[0033] Such preparations may include complexing agents, metal ions, polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, etc., liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroplasts. Lipids suitable for liposome preparations include, but are not limited to, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponins, bile acids, etc. The presence of these additional components may affect their physical state, solubility, stability, in vivo release rate, and in vivo clearance, and therefore should be selected according to the intended use so that the characteristics of the carrier are suitable for the selected route of administration.
[0034] When administered orally in liquid form, a liquid carrier such as water, petroleum, oil of animal or plant origin, such as peanut oil, mineral oil, soybean oil or sesame oil or synthetic oil can be added to the active ingredient. Physiological saline solution, glucose or other sugar solutions, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol are also suitable liquid carriers. The pharmaceutical composition can also be in the form of an oil-in-water emulsion. The oil phase can be a vegetable oil such as olive oil or peanut oil, a mineral oil such as liquid paraffin, or a mixture thereof. Suitable emulsifiers include naturally occurring gums such as gum arabic and tragacanth, naturally occurring phospholipids such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides such as sorbitol monooleate, and condensation products of these partial esters with ethylene oxide such as polyoxyethylene sorbitol monooleate. The emulsion can also contain sweeteners and flavorings.
[0035] When the compound in the preferred embodiment is administered by intravenous injection, parenteral injection or other injection, it is preferably present in the form of a pyrogen-free, parenterally acceptable aqueous solution or oily suspension. The suspension can be prepared according to methods well known in the art using suitable dispersants or wetting agents and suspending agents. It is within the skill of those skilled in the art to prepare acceptable aqueous solutions with suitable pH values, isotonicity, stability, etc. A preferred pharmaceutical composition for injection preferably contains an isotonic carrier, such as 1,3-butanediol, water, isotonic sodium chloride solution, Ringer's solution, glucose solution, glucose and sodium chloride solution, lactated Ringer's solution, or other carriers known in the art. In addition, sterile fixed oils can generally be used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid can also be used in the preparation of injection preparations. The pharmaceutical composition may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those skilled in the art.
[0036] The duration of the injection can be adjusted depending on a variety of factors and can include a single injection administered in a few seconds or less, to continuous intravenous infusion over 0.5, 0.1, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours or longer.
[0037] As used herein, the terms "treat," "therapy," or "treatment" refer to the administration of a compound or pharmaceutical composition to a subject for preventive and / or therapeutic purposes. The term "prophylactic treatment" refers to the treatment of a subject who does not yet show symptoms of a disease or condition, but is susceptible to or at risk for a particular disease or condition, thereby reducing the likelihood that the patient will develop the disease or condition. The term "therapeutic treatment" refers to the treatment of a subject who already has a disease or condition.
[0038] Overview
[0039] Embodiments of the present invention may include a container containing a liquid formulation, the liquid formulation comprising Plinabulin, propylene glycol, and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In some embodiments, the container is configured to block at least 85% of UV / visible light between 290nm and 450nm. In some embodiments, the container can be a disposable amber glass vial.
[0040] In some embodiments, the amber glass vial may include a rubber stopper and a flip top. In some embodiments, the rubber stopper may be a chlorobutyl rubber stopper with a B2-40 coating. In some embodiments, the rubber stopper may include a plug portion. In some embodiments, the plug portion may include a Flurotec coating. In any of the above embodiments, the container may include a liquid formulation comprising Plinabulin, propylene glycol, and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In any of the above embodiments, the container may include a liquid formulation comprising Plinabulin and any other suitable liquid formulation.
[0041] In some embodiments, the container may be an IV bag covered by a light-shielding sleeve. In some embodiments, the container may be an IV bag. In some embodiments, the container may be an IV tube located within a light-shielding sleeve. In some embodiments, the concentration of Plinabulin in the liquid formulation may be about 40 mg / 10 ml. In any of the above embodiments, the container may include a liquid formulation comprising Plinabulin, propylene glycol, and polyethylene glycol 15 hydroxystearate (PEG1 5-hydroxystearate). In any of the above embodiments, the container may include a liquid formulation comprising Plinabulin and any other suitable liquid formulation.
[0042] In some embodiments, the container of any of the above embodiments may contain propylene glycol and polyethylene glycol 15 hydroxystearate (PEG1 5-hydroxystearate) in a ratio of 60:40 (weight percentage). In some embodiments, the container of any of the above embodiments may contain a liquid preparation, which may contain less than 0.5% of ether impurities. In any of the above embodiments, the container may include a liquid preparation containing Plinabulin, propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In any of the above embodiments, the container may include a liquid preparation containing Plinabulin and any other suitable liquid preparation.
[0043] In some embodiments, the liquid formulation may contain less than 0.5% alcohol impurities. In some embodiments, the liquid formulation may contain less than 0.5% water. In some embodiments, the liquid formulation may contain less than 2.0% total impurities. In any of the above embodiments, the container may include a liquid formulation comprising Plinabulin, propylene glycol, and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In any of the above embodiments, the container may include a liquid formulation comprising Plinabulin and any other suitable liquid formulation.
[0044] Embodiments of the present invention may also include a kit comprising Plinabulin placed in a light-proof container. Embodiments may also include light-proof packaging. In some embodiments, the light-proof container blocks at least 85% of ultraviolet / visible light between 290nm and 450nm. In some embodiments, the concentration of Plinabulin in the liquid formulation may be about 40mg / 10ml. In any of the above kit embodiments, the container may include a liquid formulation comprising Plinabulin, propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In any of the above embodiments, the container may include a liquid formulation comprising Plinabulin and any other suitable liquid formulation.
[0045] In some embodiments, the Plinabulin may be in a liquid formulation containing propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In some embodiments, the liquid formulation may include 60:40 (weight percent) of propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In some embodiments, the light-proof container may be an amber vial.
[0046] In some embodiments, the light-proof container may include a rubber stopper and a flip cover. In some embodiments, the rubber stopper may be a chlorobutyl rubber stopper with a B2-40 coating. In some embodiments, the rubber stopper may include a plug head portion. In some embodiments, the plug head portion may include a Flurotec coating.
[0047] In some embodiments, the light-proof packaging may include solid black printing on the interior thereof. In some embodiments, the kit may further include an IV bag. In some embodiments, the IV bag may be configured to block at least 85% of UV / visible light between 290 nm and 450 nm.
[0048] In some embodiments, the IV bag may include a light shielding sleeve. In some embodiments, the kit may further include an IV tube. In some embodiments, the IV tube may be configured to block at least 85% of UV / visible light between 290 nm and 450 nm. In some embodiments, the IV tube may include a light shielding sleeve.
[0049] Embodiments of the present invention may also include methods of administering Plinabulin to a subject in need thereof, the methods comprising providing Plinabulin in a light-proof IV bag. Embodiments may also include administering Plinabulin to a subject in need thereof via a light-proof IV tube. In some embodiments, the light-proof IV bag blocks at least 85% of UV / visible light between 290 nm and 450 nm. Any of the above embodiments involving kits and formulations may be conveniently used to implement the methods of the present invention.
[0050] In some embodiments, the light-proof IV tube blocks at least 85% of UV / visible light between 290 nm and 450 nm. In some embodiments, the method of any one of 1 to 32. In some embodiments, providing the Plinabulin may include injecting the Plinabulin into a light-proof IV bag. In some embodiments, the Plinabulin may be injected into D5W as a liquid formulation.
[0051] In some embodiments, the liquid formulation may include propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In some embodiments, the liquid formulation may include propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate) in a ratio of 60:40 (weight percentage). In some embodiments, the liquid formulation may include Plinabulin at a concentration of about 40 mg / 10 ml.
[0052] In some embodiments, providing the plinabulin may include injecting the plinabulin into a non-light-shielding IV bag and then placing a light-shielding sleeve over the non-light-shielding IV bag. In some embodiments, the method may include placing a non-light-shielding IV tube within a light-shielding sleeve to form a light-shielding IV tube.
[0053] Light-proof container
[0054] In some embodiments, Plinabulin is provided to the caregiver as a liquid formulation. In some embodiments, the Plinabulin liquid formulation includes solvents polyethylene glycol 15 hydroxystearate and propylene glycol. In some embodiments, the solvent comprises 40% by weight of polyethylene glycol 15 hydroxystearate and 60% by weight of propylene glycol. In some embodiments, the concentration of Plinabulin in the liquid formulation is 40 mg / 10 ml. Studies have found that such liquid formulations of Plinabulin are extremely sensitive to light. Therefore, in some embodiments, the Plinabulin liquid formulation is provided in a light-proof container.
[0055] In some embodiments, the light-proof container is configured to block or reduce the transmission of ultraviolet / visible light. In some embodiments, the light-proof container is configured to preferentially block or reduce the transmission of ultraviolet / visible light below a specific wavelength (e.g., below 520nm). In some embodiments, the light-proof container is configured to block at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, at least 90%, at least 85%, at least 80% of ultraviolet / visible light (in some embodiments, ultraviolet / visible light below 520nm), or include and / or cover the range of the above values. In some embodiments, containers for packaging liquid preparations for parenteral and oral use should be made of materials that are sufficiently transparent at certain wavelengths to allow visual inspection of the contents.
[0056] In some embodiments, the light-proof container is configured to block or reduce the transmission of ultraviolet / visible light below 580nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of ultraviolet / visible light below 520nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of ultraviolet / visible light below 450nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of ultraviolet / visible light below 400nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of ultraviolet / visible light below 315nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of ultraviolet / visible light below 280nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of light with a wavelength from about 100nm to about 580nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of light with a wavelength from about 100nm to about 400nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of light with a wavelength from about 290nm to about 450nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of light with a wavelength from about 100 nm to about 315 nm. In some embodiments, the light-proof container is configured to block or reduce the transmission of light with a wavelength from about 100 nm to about 280 nm. In various embodiments, the above-mentioned reduction in light transmittance at a specified wavelength is at least reduced by 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65% or 60%. In some embodiments, the light-proof container is configured so that the maximum spectral transmittance percentage at any wavelength between 290 nm and 450 nm is less than 25%, 20%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6% or 5%.
[0057] In some embodiments, the light-proof container is an amber bottle. In some embodiments, the light-proof container is an amber polypropylene bottle. In some embodiments, the light-proof container is an amber glass vial. In some embodiments, the light-proof container is a borosilicate glass vial. In some embodiments, the light-proof container is a low-actinic glass vial. In some embodiments, the light-proof container is a soda-lime glass vial. In some embodiments, the light-proof container is a disposable vial.
[0058] In some embodiments, the light-proof container comprises a coating. In some embodiments, the coating is an ethylene-acrylate coating. In some embodiments, the coating is a polytetrafluoroethylene (PTFE) liner.
[0059] In some embodiments, the light-proof container comprises a flip-top lid. In some embodiments, the light-proof container comprises a polypropylene stopper sealing lid. In some embodiments, the light-proof container comprises a rubber stopper. In some embodiments, the rubber stopper is a chlorobutyl rubber stopper with a B2-40 coating. In some embodiments, the rubber stopper comprises a stopper head portion. In some embodiments, the stopper head portion comprises a coating. In some embodiments, the coating is a Flurotec coating. In some embodiments, the light-proof container comprises a rubber lined cap. In some embodiments, the rubber lined cap is a black phenolic rubber lined cap.
[0060] Light-proof packaging
[0061] In some embodiments, the light-proof container is additionally provided to the caregiver in a light-proof packaging. In some embodiments, the light-proof packaging is a UV / visible light blocking packaging. In some embodiments, the light-proof packaging is configured to block at least 99%, 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, at least 90% of UV / visible light, at least 85% of UV / visible light, at least 80% of UV / visible light, or a range including and / or covering the above values.
[0062] In some embodiments, the light-proof packaging includes a box (e.g., a cardboard box). In some embodiments, the box includes a coating that provides light-proof properties. The coating can be inside or outside the box. In some embodiments, the coating is printed on cardboard. In some embodiments, the printing includes pure black printing inside the box. Figure 1 One embodiment of a cassette as described herein is shown. Figure 1 A piece of cardboard cut to be bent into a box shape is described. One side of the cardboard has solid black printing. The cardboard can be folded into a box shape, and the inside of the box has solid black printing. Subsequently, a light-proof container (e.g., an amber vial) containing a liquid formulation of Plinabulin can be placed in the box. The light-proof effect imparted by the box enhances the light-proof effect provided by the light-proof container.
[0063] In some embodiments, the light-proof container and packaging are capable of storing the Plinabulin liquid formulation for a long period of time, while the liquid formulation maintains less than 5.0%, less than 4.5%, less than 4.0%, less than 3.5%, less than 3.0%, less than 2.5%, less than 2.0%, less than 1.5%, less than 1.0%, less than 0.5% (weight percentage) of total impurities, or a range including and / or covering the above values. In some embodiments, the stored Plinabulin liquid formulation contains less than 0.5% ether impurities. In some embodiments, the Plinabulin liquid formulation contains less than 0.5% alcohol impurities. In some embodiments, the liquid formulation contains less than 0.5% water.
[0064] Light-protection dosing regimen
[0065] Due to the extreme sensitivity of the liquid formulation of Plinabulin to light, it is also found necessary to protect the liquid formulation throughout the dosing regimen. Therefore, in some embodiments, Plinabulin is kept in a light-proof container throughout the dosing process.
[0066] In some embodiments, the light-proof container is an IV bag configured to block ultraviolet / visible light as described above. In some embodiments, the IV bag is a translucent amber IV bag. In some embodiments, the IV bag is a dark amber bag. In some embodiments, the IV bag is a light amber bag. In some embodiments, the light-proof container is an IV bag covered by a light-shielding sleeve. Figure 2 An example of a light shielding sleeve for an IV bag is shown.
[0067] In some embodiments, the light-proof container is an IV tube configured to block UV / visible light as described above. In some embodiments, the IV tube is a translucent amber IV tube. In some embodiments, the IV tube is a dark amber tube. In some embodiments, the IV tube is a light amber tube. In some embodiments, the light-proof container is an IV tube covered by a light-shielding sleeve. Figure 3 An example of a light shielding sleeve for an IV tube is shown.
[0068] Some embodiments include adding the Plinabulin liquid formulation contained in the above-mentioned light-proof vial to a light-proof IV bag. Some embodiments include administering Plinabulin to a subject in need thereof from a light-proof IV bag through a light-proof IV tube. In some embodiments, the method includes gently mixing the light-proof IV bag several times to ensure adequate mixing.
[0069] In some embodiments, the light-proof IV bag comprises D5W (5% dextrose in water) liquid formulation prior to the addition of Plinabulin. In various embodiments, the IV bag comprises 150 ml, 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml, 500 ml of D5W, or a range including and / or encompassing the above values. In some embodiments, after the addition of the Plinabulin liquid formulation from the light-proof vial, the light-proof IV bag comprises a concentration of about 0.08 mg / ml to about 0.2 mg / ml of the Plinabulin liquid formulation.
[0070] In some embodiments, a method of administering Plinabulin to a subject in need thereof comprises providing Plinabulin in a light-proof IV bag and administering Plinabulin to a subject in need thereof through a light-proof IV tube. In some embodiments, the light-proof IV bag blocks at least 85% of UV / visible light between 290nm and 450nm. In some embodiments, the light-proof IV tube blocks at least 85% of UV / visible light between 290nm and 450nm. In some embodiments, providing the Plinabulin comprises injecting the Plinabulin into a light-proof IV bag. In some embodiments, providing the Plinabulin comprises injecting the Plinabulin into a non-light-proof IV bag and then placing a light-shielding sleeve on the non-light-proof IV bag. In some embodiments, the Plinabulin is injected into D5W in a light-proof IV bag as a liquid formulation. In some embodiments, the liquid formulation comprises propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate). In some embodiments, the liquid formulation comprises propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate) in a ratio of 60:40 (by weight). In some embodiments, the liquid formulation contains Plinabulin at a concentration of about 40 mg / 10 ml. In some embodiments, the method may further comprise placing a non-light-shielding IV tube in a light-shielding cannula to form a light-shielding IV tube.
[0071] In some embodiments, the Plinabulin liquid formulation in the IV bag can be administered within 6 hours after preparation. In some embodiments, the Plinabulin is maintained at room temperature during administration to a subject in need thereof.
[0072] Stable Plinabulin composition
[0073] In some embodiments, the liquid formulation of Plinabulin in the light-proof container is a stable formulation of Plinabulin. In some embodiments, the stable formulation is stable for a storage period of at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 12 months, at least about 18 months, at least about 24 months, at least about 36 months, or at least about 48 months. In some embodiments, the stable formulation maintains at least about 99%, 95%, 90%, 80%, 70% or 60% of the Plinabulin concentration after the storage period.
[0074] In some embodiments, the stable formulations and stable pharmaceutical formulations described herein are stable when stored for a period of time at any one or more temperatures of -20°C, -10°C, 0°C, 5°C, 10°C, 25°C, 20°C, 30°C, 40°C, or a range including and / or encompassing the above values.
[0075] Application and Methods
[0076] - Some embodiments relate to methods of stopping or reversing progressive cancer in a subject. In some embodiments, the method comprises administering Plinabulin to the subject. Some embodiments relate to methods of inhibiting cancer progression. Further uses of Plinabulin include those described in U.S. Patent Nos. 7,919,497, 10,238,650, 10,155,748, 10,076,518, and 10,596,169; and PCT Publication Nos. WO 2016 / 130839, WO 2017 / 214052, WO 2018 / 144764, WO 2018 / 169887, WO 2019 / 147615, WO 2019 / 147615, WO 2019 / 152530, WO 2020 / 037285, WO 2021 / 076485, and WO 2021 / 225908; all of which are incorporated herein by reference in their entirety.
[0077] In some embodiments, the treatment regimen comprises administering Plinabulin once every 1, 2, 3, 4, 5, 6, 7, or 8 weeks. In some embodiments, the treatment regimen comprises administering Plinabulin twice every 1, 2, 3, 4, 5, 6, 7, or 8 weeks. In some embodiments, the treatment regimen comprises administering Plinabulin once every week in a treatment cycle of 1, 2, 3, 4, 5, 6, 7, or 8 weeks. In some embodiments, the treatment regimen comprises administering Plinabulin twice every week in a treatment cycle of 1, 2, 3, 4, 5, 6, 7, or 8 weeks. In some embodiments, the treatment regimen comprises administering Plinabulin on Day 1, Day 8, and Day 15 of a 21 day treatment cycle.
[0078] The treatment cycle can be repeated as long as the treatment regimen is clinically tolerated. In some embodiments, the treatment cycle of Plinabulin is repeated n times, where n is an integer in the range of 2 to 30. In some embodiments, n is 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, a new treatment cycle can occur immediately after the previous treatment cycle is completed. In some embodiments, a new treatment cycle can occur within a period of time after the previous treatment cycle is completed. In some embodiments, a new treatment cycle can occur 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, or 7 weeks after the previous treatment cycle is completed.
[0079] In some embodiments, the method comprises administering about 5 mg / m 2 Up to 150 mg / m 2 In some embodiments, Plinabulin is administered at a dose of greater than 30 mg / m 2 In some embodiments, Plinabulin is administered at a dose of about 40 mg / m 2 dosage administration.
[0080] In some embodiments, Plinabulin is administered on Day 1 of a 14-day dosing cycle. In some embodiments, Plinabulin is administered on Day 1 of a 21-day dosing cycle.
[0081] In some embodiments, the Plinabulin liquid formulation is co-administered with one or more G-CSF drugs. In some embodiments, the one or more G-CSF drugs are paclitaxel.
[0082] Reagent test kit
[0083] Some embodiments include kits comprising one or more containers.
[0084] In some embodiments, the container comprises plastic or glass, or a combination thereof, including but not limited to any one or more of the plastic or glass used by those skilled in the art as taught herein. In some embodiments, the portion of the container in contact with the liquid formulation is made of amber glass. In some embodiments, the container is dyed amber. In some embodiments, the container is opaque or translucent to protect the formulation from light or other forms of radiation, and is also accompanied by a transparent or translucent portion. In some embodiments, the dosage kit and packaging are selected from the group consisting of an amber vial to protect from light and a stopper with a special coating to improve shelf life stability.
[0085] In some embodiments, the container is a vial. In some embodiments, the vial contains Plinabulin in an amount of about 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, or a range including and / or covering the above values.
[0086] In some embodiments, the container is an IV bag. In some embodiments, the IV bag includes a dark amber IV cap. In some embodiments, the IV bag blocks UV / visible light. In some embodiments, the IV bag blocks 95% of UV / visible light. In some embodiments, the IV bag is opaque. In some embodiments, the IV bag is transparent but masks differences in IV fluid color.
[0087] In some embodiments, the kit further comprises an IV tube cover. In some embodiments, the IV tube cover is an amber IV tube cover. In some embodiments, the amber IV tube cover provides additional protection for the Plinabulin composition or pharmaceutical composition.
[0088] In some embodiments, the container of the present invention is in a secondary packaging. In some embodiments, the secondary packaging is configured to maintain the stability of the therapeutic agent relative to the stability of the therapeutic agent before packaging. In some variations, the secondary packaging is designed to prevent or reduce exposure of the preparation to light. In some embodiments, the secondary packaging is designed to prevent or reduce exposure of the preparation to one or more components of the air, such as oxygen. In some variations, the container is an ampoule, a vial, or a prefilled syringe.
[0089] In some embodiments, the kit may include Plinabulin for injection in a single-use amber glass vial having a chlorobutyl rubber stopper and flip-top cap with a Flurotec coating on the tip portion of the stopper.
[0090] In some embodiments, the formulations described herein are provided in one or more unit dosage forms, wherein the unit dosage form contains an amount of the liquid Plinabulin formulation described herein that is effective for treating or preventing the disease or condition for which it is administered.
[0091] In some embodiments, the unit dosage form is prepared at its administration concentration. In some variations, the unit dosage form is diluted before administration to a subject.
[0092] On the other hand, the present invention provides a kit comprising one or more unit dosage forms of the present invention. In some embodiments, the kit includes one or more packages and instructions for treating one or more diseases or conditions. In some embodiments, the kit includes a diluent that is not in physical contact with the preparation or pharmaceutical preparation. In some embodiments, the kit includes any one of the one or more unit dosage forms of the present invention in one or more sealed containers. In some embodiments, the kit includes any one of one or more sterile unit dosage forms.
[0093] In some embodiments, the kit may contain a G-CSF drug. Granulocyte colony stimulating factor (G-CSF) refers to a compound or factor that stimulates granulocyte proliferation, differentiation, commitment, and activation of terminal cell functions in animals, including human subjects. G-CSF compounds include, but are not limited to, Filgrastim and Pegfilgrastim. Examples of commercially available G-CSF include, but are not limited to (Amgen), (Teva), (CT Arzneimittel), (Ratiopharm GmbH), (Sandoz GmbH), Filgrastim (Hexal AG), (Amgen), and (Chugai), and (Kyowa Hakko). G-CSF is commonly used to treat severe neutropenia caused by chemotherapy. G-CSF, such as pegfilgrastim, is a colony stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and activation of terminal cell functions. Example
[0094] To further describe the present invention, the following examples are given. Of course, these examples should not be construed as particularly limiting the present invention. Variations of these examples within the scope of the claims are within the scope of those skilled in the art and are considered to fall within the scope of the present invention as described and claimed. The reader will recognize that a professional having mastered the present invention and possessing the skills in the art can prepare and use the present invention without the need for detailed examples.
[0095] Example 1.
[0096] This comparative example reports stress testing of solid Plinabulin, showing its relative stability after storage under light conditions for 30 days. Table 1 reports the results of the impurity analysis of Plinabulin after exposure to light for 30 days. Table 2 reports the results of the impurity analysis of the control sample stored under dark conditions. The results show that after 30 days of exposure to light, the total impurities only increased from 0.3% to 0.6%.
[0097] Table 1
[0098]
[0099]
[0100] Table 2
[0101]
[0102] Example 2
[0103] This example shows the results of a study designed to evaluate the photostability of a 4 mg / mL (40 mg / 10 mL) liquid formulation of Plinabulin in 40% (weight percent) polyethylene glycol 15 hydroxystearate and 60% (weight percent) propylene glycol in different packaging configurations. Table 3 describes the packaging used and the results of the study are shown in Table 4.
[0104] Table 3
[0105]
[0106] The following configurations were tested:
[0107] 1) Unexposed finished product in primary packaging (control).
[0108] 2) Finished product in primary packaging wrapped in aluminum foil, exposed to UV / visible light (dark control).
[0109] 3) Finished product in primary packaging (amber vial) exposed to UV / visible light.
[0110] 4) Finished vials in secondary packaging (IFC carton) exposed to UV / visible light.
[0111] The light intensity was determined on the test day and the actual test time was recorded. Photostability studies were performed in accordance with VP 5740 and ICH Q1B: Photostability Testing of New Drug Substances and Drug Products (November 1996).
[0112] Samples of Plinabulin liquid formulation in primary packaging (amber vials) and secondary packaging (IFC cartons) were exposed to UV / visible light providing a total illumination of 1.21 million lux-hours and 326.6 watt-hours / m 2 The comprehensive near-ultraviolet energy meets the requirements of ICH Q1B Option 1, which requires a total illuminance of not less than 1.2 million lux-hours and a comprehensive near-ultraviolet energy of not less than 200 watt-hours / m 2 Unexposed control samples were evaluated for reference only. Finished product samples wrapped in aluminum foil (dark control) were exposed to light to evaluate the contribution of thermally induced changes to the total observed changes. Photostability was determined based on appearance, retention time identification, UV spectrum matching / PDA identification, moisture content, assay, impurities, container contents, and particulate matter.
[0113] At the end of the photostability study, samples were evaluated for any changes in the physical properties (i.e., appearance) of the sample liquid formulations and tested for retention time identification, UV spectrum matching / PDA identification, water content, assay, impurities, container contents, and particulate matter.
[0114] Table 4
[0115]
[0116]
[0117]
[0118] The results for the assay and individual and total impurities did not meet the acceptance criteria for the primary packaging (amber vial), indicating that the primary packaging did not provide adequate protection from light. All other results for the control, dark control, and secondary packaging (IFC carton) met the specified acceptance criteria.
[0119] Based on the results generated, it can be concluded that placing the amber vials in the IFC carton provides adequate light protection for the 4 mg / mL (40 mg / 10 mL) Plinabulin liquid formulation.
[0120] Example 3
[0121] This example reports the results of a study designed to determine the effects of light exposure on the appearance, ID, assay, and impurities of a Plinabulin liquid formulation in an infusion tube after dilution of the 4 mg / ml liquid formulation (40% by weight polyethylene glycol 15 hydroxystearate and 60% by weight propylene glycol) at 1:20 and 1:50 in a 5% dextrose in water (D5W) infusion bag. The target illumination on the infusion tube was 1000 lux per ANSI / IES RP-29-20 (Recommended Practice: Lighting in Hospitals and Healthcare Facilities, American National Standard).
[0122] The study used 200-500 mL non-PVC bags with dilution ratios of 1:20 and 1:50 and was conducted at different time intervals. Plinabulin liquid formulation, 4 mg / mL, was diluted in D5W at dilution levels of 1:20 and 1:50. Dilutions were performed using clear vials of 4 mg / mL Plinabulin liquid formulation. After illumination, samples were removed from the infusion line at the following time intervals: 3 minutes, 5 minutes, 7 minutes, 11 minutes, 14 minutes, and 22 minutes. At the 0 minute time point, a control sample was removed from the outlet of the D5W bag containing the diluted Plinabulin drug product (T=0).
[0123] Materials and methods
[0124] Plinabulin Liquid Formulation 4mg / mL: 10ml amber vial. D5W Liquid Formulation: 200-500ml sterile D5W bags in non-PVC bags, B.Braun, lot #J9N016. Dark amber D5W bag covers: Healthcare Logistics item #7589D. Amber IV Tube Sets: Amber tube covers rolled to 72 and 103 inches, Healthcare Logistics item #19645. Liquid Formulation Set with DUO-VENTspike Needle, Polyethylene Lined Tube 103 inches, Baxter item #2C8875. Light Intensity Meter ID#2359506.
[0125] Sampling Procedure
[0126] All manipulations were performed in a dark room; the liquid formulations were not heated or refrigerated once diluted. All D5W non-PVC IV bags used in the study were from the same manufacturer / supplier and from the same manufacturer's batch. Infusion bags were prepared for the study. Plinabulin liquid formulation, 4 mg / mL, was diluted 1:20 or 1:50 with D5W in non-PVC IV bags to make diluted IV infusion formulations (infusion bags).
[0127] Preparation of infusion preparations
[0128] Measure and record the IV drip volume: 7 mL for 72-inch lines; 10 mL for 103-inch lines. Take a D5W IV bag and place a light-protective sleeve over the D5W IV bag and tubing sleeve. Use a Luer lock syringe to withdraw the required volume from the vial. Immediately dilute the required volume of drug product into a light-protected D5W bag containing 200-500 mL of D5W according to the label statement to the desired dilution of 1:20 or 1:50. Gently invert the IV bag several times to ensure thorough mixing. Visually confirm that the resulting dilution is a clear liquid formulation. Take a sample from each prepared bag for TA time point 0, transfer to a labeled sample container and protect from light. Fill a separate IV tube for each time point from the prepared IV bag, these samples are used to test the effect of light exposure on bare IV tubes and IV tubes protected with amber sleeves. Filled IV tubes are light-protected and properly labeled before exposure to white light.
[0129] Exposure Procedure
[0130] All operations were performed in a darkroom. The darkroom was equipped with a white light. The light intensity was measured and recorded at the beginning of the sample exposure. The target illumination at the exposure site (infusion tube) was 1000 lux according to ANSI / IES RP-29-20. Table 5 describes the light intensity measurements.
[0131] Table 5
[0132]
[0133] The Plinabulin injection samples were diluted with D5W in a non-PVC bag at a dilution ratio of 1:20 and 1:50, and then filled into bare infusion tubes and infusion tubes wrapped in amber sleeves at room temperature, and exposed to light for a certain period of time by turning on white light for a predetermined time.
[0134] Detection scheme
[0135] All samples except the T=0 sample were exposed to light under the above conditions. Light-protected conditions for filled IV lines: Bare tubing (unprotected): 72 inches; Bare tubing (unprotected): 103 inches; Amber sleeve IV line: 72 inches; and Amber sleeve IV line: 103 inches. The entire contents of each IV line were transferred to a pre-labeled amber sample container and stored at room temperature, protected from light, until analytical testing. Samples were tested within 6 hours of product dilution. Samples were tested as described herein.
[0136] Test methods and acceptance criteria
[0137] Impurities / degradants were determined by high performance liquid chromatography (HPLC). During the tubing illumination study, samples were taken from a single tubing or outlet (if applicable) and tested directly without further dilution and / or filtration. The acceptance criteria and results for the tubing illumination study are shown in Table 6 (1:20 dilution) and Table 7 (1:50 dilution).
[0138] Table 6
[0139]
[0140]
[0141]
[0142]
[0143] Table 7
[0144]
[0145]
[0146]
[0147]
[0148]
[0149] The results for the NPI-2489 impurity indicated that the bare IV tubing did not meet the NMT 0.5% acceptance criteria at 72 inches and 103 inches, except for the 1-minute time point at 72 inches. All other results met the specified acceptance criteria. Based on the data from this study, it can be concluded that the results produced using bare IV tubing do not meet the specification acceptance criteria for the NPI-2489 impurity and that the placement of an amber IV tubing cover over the tubing provides adequate light protection for up to 22 minutes.
[0150] Example 4
[0151] In this comparative example, it can be seen that solid Plinabulin is not photosensitizing. Table 8 shows the stability of solid Plinabulin in photosensitization studies.
[0152] Table 8
[0153]
Claims
1. A container, It is characterized in that include: A liquid formulation containing plinabulin, propylene glycol, and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate); Wherein, the container is configured to block at least 85% of ultraviolet / visible light between 290nm and 450nm.
2. The container according to claim 1, It is characterized in that The container is a disposable amber glass vial.
3. The container according to claim 2, It is characterized in that The amber glass vial further comprises a rubber stopper and a flip top.
4. The container according to claim 3, It is characterized in that The rubber stopper is a chlorobutyl rubber stopper with a B2-40 coating.
5. The container according to claim 3 or 4, It is characterized in that The rubber stopper further comprises a stopper head portion, wherein the stopper head portion comprises a Flurotec coating.
6. The container according to claim 1, It is characterized in that The container is an IV bag.
7. The container according to claim 3, It is characterized in that The container is an IV bag covered by a light-shielding sleeve.
8. The container according to claim 1, It is characterized in that The container is an IV tube in a light-proof sleeve.
9. The container according to any one of claims 1 to 8, It is characterized in that The concentration of Plinabulin in the liquid preparation is about 40 mg / 10 ml.
10. The container according to any one of claims 1 to 9, It is characterized in that The container includes propylene glycol and polyethylene glycol 15 hydroxystearate (PEG15-hydroxystearate) in a ratio of 60:40 (by weight).
11. The container according to any one of claims 1 to 10, It is characterized in that The liquid formulation contains less than 0.5% ether impurities.
12. The container according to any one of claims 1 to 11, It is characterized in that The liquid formulation contains less than 0.5% alcohol impurity.
13. The container according to any one of claims 1 to 12, It is characterized in that The liquid formulation contains less than 0.5% water.
14. The container according to any one of claims 1 to 13, It is characterized in that The liquid formulation contains less than 2.0% total impurities.
15. A kit, It is characterized in that include: Plinabulin in a light-proof container; and - Light-proof packaging, The light-proof container blocks at least 85% of ultraviolet light / visible light between 290nm and 450nm.
16. The kit according to claim 15, It is characterized in that The concentration of Plinabulin in the liquid preparation is about 40 mg / 10 ml.
17. The kit according to claim 15 or 16, It is characterized in that The Plinabulin is in a liquid formulation containing propylene glycol and polyethylene glycol 15 hydroxystearate (PEG 15-hydroxystearate).
18. The kit according to claim 17, It is characterized in that The liquid preparation includes propylene glycol and polyethylene glycol 15-hydroxystearate (PEG15-hydroxystearate) in a ratio of 60:40 (weight ratio).
19. The kit according to any one of claims 15 to 18, It is characterized in that The light-proof container is an amber vial.
20. The kit according to any one of claims 15 to 19, It is characterized in that The light-proof container further comprises a rubber stopper and a flip cover.
21. The kit according to claim 20, It is characterized in that The rubber stopper is a chlorobutyl rubber stopper with a B2-40 coating.
22. The kit according to claim 20 or 21, It is characterized in that The rubber stopper further comprises a stopper head portion, wherein the stopper head portion comprises a Flurotec coating.
23. The kit according to any one of claims 15 to 22, It is characterized in that The light-proof packaging includes solid black printing on its interior.
24. The kit according to any one of claims 15 to 23, It is characterized in that The kit further includes an IV bag.
25. The kit according to claim 24, It is characterized in that The IV bag is configured to block at least 85% of UV / visible light between 290 nm and 450 nm.
26. The kit according to claim 25, It is characterized in that The IV bag includes a light blocking sleeve.
27. The kit according to any one of claims 15 to 26, It is characterized in that The kit further includes an IV tube.
28. The kit according to claim 27, It is characterized in that The IV tube is configured to block at least 85% of UV / visible light between 290 nm and 450 nm.
29. The kit according to claim 28, It is characterized in that The IV tube includes a light shielding sleeve.
30. A method of administering Plinabulin to a subject in need thereof, It is characterized in that The method includes: Provide Plinabulin in a light-protected IV bag; and Plinabulin was administered to subjects in need via a light-protected IV tube.
31. The method of claim 30, It is characterized in that The light-proof IV bag blocks at least 85% of UV / visible light between 290 nm and 450 nm.
32. The method of claim 30 or 31, It is characterized in that The light-proof IV tube blocks at least 85% of UV / visible light between 290 nm and 450 nm.
33. The method according to any one of claims 30 to 32, It is characterized in that The providing of Plinabulin comprises injecting the Plinabulin into a light-protected IV bag.
34. The method of any one of claims 30 to 32, It is characterized in that The providing of Plinabulin comprises injecting the Plinabulin into a non-light-protecting IV bag and subsequently placing a light-blocking sleeve over the non-light-protecting IV bag.
35. The method of claim 33 or 34, It is characterized in that The Plinabulin was injected as a liquid formulation in D5W.
36. The method of claim 35, It is characterized in that The liquid formulation contains propylene glycol and polyethylene glycol 15 hydroxystearate (PEG 15-hydroxystearate).
37. The method of claim 36, It is characterized in that The liquid preparation contains propylene glycol and polyethylene glycol 15-hydroxystearate (PEG15-hydroxystearate) in a ratio of 60:40 (weight ratio).
38. The method of any one of claims 35 to 37, It is characterized in that The liquid formulation includes Plinabulin at a concentration of about 40 mg / 10 ml.
39. The method according to any one of claims 30 to 38, It is characterized in that The method includes placing a non-light-shielding IV tube in a light-shielding sleeve to form a light-shielding IV tube.
